Elevance Health IncELV

Why is Elevance Health (ELV) moving?

Q3 202629 Jun – 13 Sep 2026

▼3▲1

Elevance beats Q2, raises guidance, but Medicaid losses and member drop weigh

Q2 earnings beat and raised 2026 guidance Elevance beat Q2 earnings and raised its 2026 profit outlook to at least $27 per share, backed by $4.3 billion in quarterly operating cash flow, buybacks, and dividends.
This is the main positive event that drove the stock during the period.
Medicaid margins turn negative, prompting market exits Medicaid margins turned negative at -1.75%, forcing Elevance to exit some markets. This raises concerns about profitability in government programs and pressures the stock.
This is a key negative development that hurt investor sentiment.
Suing CMS over $115M in lost Medicare Advantage bonuses Elevance is suing CMS over $115 million in lost Medicare Advantage bonuses. The lawsuit adds regulatory uncertainty and could affect future earnings if not resolved favorably.
This new legal action is a notable negative factor for the stock.
Q3 earnings expected down ~30% year-over-year, stock falls 7.4% Q3 earnings are expected to drop about 30% from a year ago, and the stock fell 7.4% despite a $49.83 billion revenue beat. The company also lost 469,000 members.
This captures the market's negative reaction and the member loss, which are new developments.

August 202611 Jul – 13 Sep 2026

▼2▲1

Elevance's 2026 profit squeeze may be bottoming as 2027 recovery bets build

2026 earnings forecast cut, but stock already ran Analysts now expect Elevance to earn $6.18 a share this quarter, down about 30% from a year ago, with revenue forecasts also slipping. That is the near-term drag. But the stock had already climbed 33.6% in 90 days, so much of the bad news may be priced in.
This is the core reason the stock is under pressure: falling profit expectations for 2026.
Margins seen bottoming in 2026, recovery in 2027 Greenskeeper Asset Management says Elevance's operating margins may have hit bottom this year. Medical cost inflation is stabilizing, government payment updates are better than feared, and the company is repricing plans to match costs. That sets up an earnings rebound in 2027, which is why long-term investors are looking past this year's weak profit.
This explains the bull case: the profit downturn is temporary and a recovery is coming next year.
Industry cost trends split: some relief, some pressure UnitedHealth's medical costs fell sharply, helping its earnings and lifting the whole managed-care group. But CVS Health warned that its medical costs remain high, which dragged Elevance and peers down. Elevance's own cost ratio rose slightly, yet it still raised its 2026 profit guidance to at least $27 a share. The picture is uneven.
Shows the tug-of-war on medical costs that directly drives Elevance's profit and stock price.
Lost 469,000 members even as revenue beat Elevance beat revenue expectations with $49.83 billion, but lost 469,000 customers and the stock fell 7.4%. Losing members shrinks the base of people paying premiums, which matters more for future growth than a one-quarter revenue beat. Investors focused on the membership decline.
Membership loss is a concrete negative that pressures future revenue and the stock.

Latest11 Jul – 13 Sep 2026

▼2▲1

Elevance's 2026 profit squeeze may be bottoming as 2027 recovery bets build

2026 earnings forecast cut, but stock already ran Analysts now expect Elevance to earn $6.18 a share this quarter, down about 30% from a year ago, with revenue forecasts also slipping. That is the near-term drag. But the stock had already climbed 33.6% in 90 days, so much of the bad news may be priced in.
This is the core reason the stock is under pressure: falling profit expectations for 2026.
Margins seen bottoming in 2026, recovery in 2027 Greenskeeper Asset Management says Elevance's operating margins may have hit bottom this year. Medical cost inflation is stabilizing, government payment updates are better than feared, and the company is repricing plans to match costs. That sets up an earnings rebound in 2027, which is why long-term investors are looking past this year's weak profit.
This explains the bull case: the profit downturn is temporary and a recovery is coming next year.
Industry cost trends split: some relief, some pressure UnitedHealth's medical costs fell sharply, helping its earnings and lifting the whole managed-care group. But CVS Health warned that its medical costs remain high, which dragged Elevance and peers down. Elevance's own cost ratio rose slightly, yet it still raised its 2026 profit guidance to at least $27 a share. The picture is uneven.
Shows the tug-of-war on medical costs that directly drives Elevance's profit and stock price.
Lost 469,000 members even as revenue beat Elevance beat revenue expectations with $49.83 billion, but lost 469,000 customers and the stock fell 7.4%. Losing members shrinks the base of people paying premiums, which matters more for future growth than a one-quarter revenue beat. Investors focused on the membership decline.
Membership loss is a concrete negative that pressures future revenue and the stock.

July 202629 Jun – 16 Jul 2026

▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.
This is the core reason the stock fell after earnings and is the main new negative force.
Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.
This is a new legal and regulatory risk that directly affects a revenue source.
Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.
This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.
Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.
This is a new capital-return update that provides a positive counterweight to the margin issues.

29 Jun – 16 Jul 2026

▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.
This is the core reason the stock fell after earnings and is the main new negative force.
Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.
This is a new legal and regulatory risk that directly affects a revenue source.
Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.
This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.
Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.
This is a new capital-return update that provides a positive counterweight to the margin issues.

Q2 202618 Jun – 26 Jun 2026

▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.
This is a new operational improvement that directly lowers costs and supports earnings growth.
Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.
Carelon's growing contribution and raised guidance are key positive drivers for future earnings.
CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.
New partnership expands covered lives and service portfolio, a direct demand driver.
No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.
This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

June 202618 Jun – 26 Jun 2026

▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.
This is a new operational improvement that directly lowers costs and supports earnings growth.
Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.
Carelon's growing contribution and raised guidance are key positive drivers for future earnings.
CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.
New partnership expands covered lives and service portfolio, a direct demand driver.
No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.
This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

18 Jun – 26 Jun 2026

▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.
This is a new operational improvement that directly lowers costs and supports earnings growth.
Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.
Carelon's growing contribution and raised guidance are key positive drivers for future earnings.
CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.
New partnership expands covered lives and service portfolio, a direct demand driver.
No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.
This highlights a regulatory and cost risk that could negatively impact Elevance's margins.